Xitra Therapeutics focuses on the discovery and development of small molecules that target the Mas and MrgD receptors in the Alternative Renin Angiotensin System.

These molecules act like the naturally occurring peptide, angiotensin-(1-7), but have superior drug properties including increased potency and oral bioavailability.

Xitra Therapeutics is a subsidiary of Constant Therapeutics.

Xitra Therapeutics GmbH is proud to announce that the TBI Technologie-Beratungs-Institut GmbH approved our proposal and that the State Mecklenburg-Western Pomerania has supported the Research & Development programs of the company with 850,000 Euro. The Minister of Economics, Infrastructure, Tourism, and Labour, Reinhard Meyer, sent the approval letter in July 2022, and we are proud to be supported by these organizations.

Entwicklung von oral applizierbaren Ang-(1-7)-Agonisten zur Behandlung von Volkskrankheiten und seltenen Erkrankungen (TBI-V-1-440-E)